S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
MBX · MBX Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
MBX Biosciences Inc (MBX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$53.90
+0.48
(+0.90%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$53.90
$53.45
$55.73
52-WEEK RANGE
$53.90
$14.26
$72.64
What's happening
- MBX is up 0.90% today, trading at $53.90. — Live quote
- Volume today (28,450) is well below its 3-month average of 651,520. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.78 actual vs. $-0.64 estimated (-22.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 5
Buy 9
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MBX
+70.99%
vs S&P 500
+57.62%
1-YEAR RETURN
MBX
+252.25%
vs S&P 500
+237.09%
6-MONTH RETURN
MBX
+59.70%
3-MONTH RETURN
MBX
-7.50%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.78
Est. $-0.64
MISS -22.2%
2026-04-26 (Q1 2026)
$-0.51
Est. $-0.59
BEAT +13.3%
2026-01-26 (Q4 2025)
$-0.49
Est. $-0.62
BEAT +20.4%
2025-10-26 (Q3 2025)
$-0.63
Est. $-0.70
BEAT +10.1%
Valuation Measures & Ratios
Enterprise Value4$2.54B
Forward P/E5—
PEG Ratio6-5.05
Price / Sales (TTM1)—
Price / Book76.42
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-26.01%
Return on Assets (ROA9)-24.92%
Avg Volume (3M)651,520
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $2.62B | $1.41B | $600.7M | $3.07B | $1.98B |
| P/E | -25.82 | -15.89 | -7.23 | -39.66 | -28.15 |
| Price/Book | 6.41 | 3.21 | 1.55 | 13.98 | 8.39 |
| ROE | -24.82% | -20.20% | -21.43% | -35.25% | -29.83% |
| ROA | -23.32% | -19.53% | -20.76% | -33.38% | -28.55% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short4,466,280
Change from Prior Settlement+8.15%
% of Float—
Days to Cover (Short Ratio)6.84
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +252.3%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-08-27; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MBX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$40.9M | -$27.3M | -$23.9M | -$21.8M | -$26.5M | -$19.6M | -$16.7M | -$13.3M |
| Net income | -$37.1M | -$23.5M | -$21.6M | -$19.4M | -$23.9M | -$18.1M | -$15.9M | -$12.3M |
| EPS (diluted) | $-0.78 | $-0.50 | $-0.63 | $-0.58 | $-0.71 | $-2.78 | $-12.62 | $-10.26 |
| EPS (basic) | $-0.78 | $-0.50 | $-0.63 | $-0.58 | $-0.71 | $-2.78 | $-12.62 | $-10.26 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $435.9M | $452.7M | $385.1M | $400.1M | $231.5M | $245.9M | $268.5M | $282.4M |
| Total liabilities | $26.4M | $14.9M | $15.9M | $12.5M | $12.3M | $10.5M | $11.1M | $11.0M |
| Stockholders' equity | $409.5M | $437.8M | $369.2M | $387.5M | $219.2M | $235.4M | $257.4M | $271.4M |
| Total current assets | $427.9M | $448.5M | $381.5M | $397.5M | $229.2M | $244.3M | $267.3M | $281.2M |
| Total current liabilities | $23.7M | $14.6M | $15.5M | $12.1M | $11.8M | $10.5M | $11.1M | $10.9M |
| Cash & equivalents | $54.1M | $45.2M | $75.3M | $223.1M | $39.8M | $29.9M | $49.4M | $132.9M |
| Marketable securities (current) | $364.5M | $394.8M | $298.4M | $168.5M | $185.1M | $210.9M | $212.8M | $144.2M |
| Other current assets | $1.2M | $814.0K | $861.0K | $882.0K | $472.0K | $626.0K | $803.0K | $838.0K |
| Property, plant & equipment | $4.7M | $3.1M | $2.7M | $2.0M | $1.7M | $1.5M | $1.1M | $1.0M |
| Other non-current assets | $625.0K | $579.0K | $383.0K | $50.0K | $50.0K | $50.0K | $50.0K | $50.0K |
| Accounts payable | $4.4M | $7.0M | $3.0M | $3.8M | $5.8M | $4.2M | $5.3M | $5.0M |
| Accrued liabilities | $18.7M | $7.4M | $12.3M | $8.1M | $5.9M | $6.1M | $5.5M | $5.8M |
| Common stock & paid-in capital | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $5.0K |
| Retained earnings | -$285.1M | -$248.0M | -$224.5M | -$202.4M | -$180.8M | -$161.4M | -$137.5M | -$121.9M |
| Accumulated other comprehensive income (loss) | -$1.2M | -$606.0K | $286.0K | $154.0K | $11.0K | $53.0K | $55.0K | $106.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.6M | -$20.2M | -$18.3M | -$21.5M | -$17.4M | -$22.7M | -$16.0M | -$14.7M |
| Investing cash flow | $29.2M | -$97.1M | -$130.0M | $17.1M | $26.0M | $3.2M | -$67.3M | -$100.8M |
| Financing cash flow | $2.3M | $87.4M | $438.0K | $187.8M | $1.3M | $4.0K | -$132.0K | $235.8M |
| Free cash flow | -$23.5M | -$20.6M | -$19.1M | -$21.9M | -$18.1M | -$22.7M | -$16.1M | -$14.7M |
| Capital expenditures | $901.0K | $437.0K | $793.0K | $399.0K | $707.0K | $30.0K | $92.0K | $57.0K |
| Share-based compensation | $6.1M | $5.5M | $2.7M | $2.2M | $1.9M | $1.8M | $1.5M | $1.2M |
| Change in accounts payable | -$3.2M | $4.0M | -$861.0K | -$2.0M | $2.0M | -$1.6M | $645.0K | $2.2M |
| Purchases of investments | $53.9M | $154.2M | $205.4M | $46.4M | $47.4M | $58.9M | $87.5M | $127.7M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating income | -$98.1M | -$68.2M | -$35.3M |
| Net income | -$87.0M | -$61.9M | -$32.6M |
| EPS (diluted) | $-2.38 | $-5.82 | $-31.96 |
| EPS (basic) | $-2.38 | $-5.82 | $-31.96 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $385.1M | $268.5M | $84.2M | — |
| Total liabilities | $15.9M | $11.1M | $4.3M | — |
| Stockholders' equity | $369.2M | $257.4M | -$72.5M | -$42.6M |
| Total current assets | $381.5M | $267.3M | $83.5M | — |
| Total current liabilities | $15.5M | $11.1M | $3.9M | — |
| Cash & equivalents | $75.3M | $49.4M | $30.5M | — |
| Marketable securities (current) | $298.4M | $212.8M | $50.2M | — |
| Other current assets | $861.0K | $803.0K | $133.0K | — |
| Property, plant & equipment | $2.7M | $1.1M | $439.0K | — |
| Other non-current assets | $383.0K | $50.0K | $50.0K | — |
| Accounts payable | $3.0M | $5.3M | $1.4M | — |
| Accrued liabilities | $12.3M | $5.5M | $2.4M | — |
| Common stock & paid-in capital | $6.0K | $5.0K | $1.0K | — |
| Retained earnings | -$224.5M | -$137.5M | -$75.6M | — |
| Accumulated other comprehensive income (loss) | $286.0K | $55.0K | $60.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$79.9M | -$54.7M | -$32.0M |
| Investing cash flow | -$83.7M | -$160.6M | -$30.9M |
| Financing cash flow | $189.6M | $234.1M | $69.2M |
| Free cash flow | -$81.9M | -$55.6M | -$32.1M |
| Capital expenditures | $1.9M | $874.0K | $129.0K |
| Share-based compensation | $8.7M | $5.2M | $2.0M |
| Change in accounts payable | -$2.5M | $3.9M | $412.0K |
| Purchases of investments | $358.1M | $239.5M | $63.8M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MBX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-10-17 to 2026-08-04
Recent transactions
- Insiders have net sold 71,211 shares over the last 182 days, across 0 purchases and 5 sales.
- Most recent: Azoulay Salomon (Chief Medical Officer) — Open market sale of 370 shares on 2026-08-04.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)71,211 sh(5 txns)
Net Shares-71,211
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Azoulay Salomon | Chief Medical Officer | Open market sale | 2026-08-04 | 370 |
| Smither John W | Chief Financial Officer | Grant / award | 2026-08-03 | 28,000 |
| Hoerter Steven L. | President and CEO | Grant / award | 2026-08-03 | 71,000 |
| Hawryluk P. Kent | President & CEO | Open market sale | 2026-05-06 | 607 |
| Bartram Richard | Chief Financial Officer | Grant / award | 2026-02-02 | 15,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | Chief Medical Officer | Open market sale | 370 | $65.77 |
| 2026-08-03 | Smither John W | Chief Financial Officer | Grant / award | 28,000 | $0.00 |
| 2026-08-03 | Hoerter Steven L. | President and CEO | Grant / award | 71,000 | $0.00 |
| 2026-05-08 | Azoulay Salomon | Chief Medical Officer | Option exercise | 55,000 | $10.46 |
| 2026-05-08 | Azoulay Salomon | Chief Medical Officer | Open market sale | 55,000 | $38.38 |
| 2026-05-08 | Azoulay Salomon | Chief Medical Officer | Option exercise | 15,003 | $16.00 |
| 2026-05-08 | Azoulay Salomon | Chief Medical Officer | Open market sale | 15,003 | $38.30 |
| 2026-05-06 | Azoulay Salomon | Chief Medical Officer | Open market sale | 231 | $29.54 |
| 2026-05-06 | Hawryluk P. Kent | President & CEO | Open market sale | 607 | $29.54 |
| 2026-05-01 | Hoerter Steven L. | Reporting person | Grant / award | 11,938 | $0.00 |
| 2026-03-13 | Hawryluk P. Kent | President & CEO | Open market purchase | 18,500 | $28.41 |
| 2026-02-26 | Hawryluk P. Kent | President & CEO | Option exercise | 28,768 | $16.00 |
| 2026-02-02 | Azoulay Salomon | Chief Medical Officer | Grant / award | 15,000 | $0.00 |
| 2026-02-02 | Bartram Richard | Chief Financial Officer | Grant / award | 15,000 | $0.00 |
| 2026-02-02 | Hawryluk P. Kent | President & CEO | Grant / award | 35,250 | $0.00 |
| 2025-10-24 | Hawryluk P. Kent | President & CEO | Option exercise | 182,859 | $3.25 |
| 2025-10-20 | Hawryluk P. Kent | President & CEO | Open market purchase | 20,000 | $13.64 |
| 2025-10-17 | Hoerter Steven L. | Reporting person | Open market purchase | 20,000 | $13.25 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:46 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-27 | 8-K | 2026-08-27 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-08-05 | 4 | 2026-08-04 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-08-04 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-09 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-12 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
| 2026-06-05 | 4 | 2026-06-04 | View on SEC.gov → |
Recent news
Headlines about MBX (MBX Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
Why Microbix Biosystems Inc. Is on Investors’ Radar: Key Catalysts to Watch on TSX:MBX
kalkine.ca · 2026-10-20 -
MBX Biosciences (NASDAQ:MBX) Shares Up 6.3% - Here's Why
MarketBeat · 2026-10-19 -
(MBX) and the Role of Price-Sensitive Allocations
Stock Traders Daily · 2026-10-18 -
Learn Why The Bull Case For MBX Biosciences Stock Could Change Following Early Obesity Data
Simply Wall Street · 2026-10-17 -
MBX Biosciences to Participate in Upcoming November Investor Conferences
Yahoo · 2026-10-13 -
Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $84
Benzinga · 2026-10-12 -
Is MBX Biosciences (MBX) Still Undervalued After Its Pullback From A Strong 1 Year Run?
Yahoo · 2026-10-10 -
MBX Biosciences (MBX) Stock Could Be Above Fair Value As Shares Jumped 257%
Yahoo · 2026-10-10
No headlines in this category right now — try “All”.